ArticlePloS one2024
Advancing inclusive research calculator for oncology disease areas: A resource to support the development of enrollment targets in diversity action plans for industry sponsors.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Five Data-Informed Principles for Advancing Inclusive Research in Clinical Trials: A Pharma Perspective.Advances in therapy · 2025Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Food and Drug Omnibus Report Act, signed into law in 2022, requires industry sponsors to include diversity action plans in clinical study protocols. Defining reliable methodology for measures and benchmarks is critical to ensuring adequate and consistent representation of historically underrepresented patient populations in clinical trials.
methodsWe provide an Advancing Inclusive Research (AIR) Calculator, summary tables, and data query bank to support target setting for the development of diversity action plans and to take steps toward defining enrollment standards. The AIR Calculator uses data from the US Cancer Statistics database, which covers 100% of the US population. The database provides descriptive statistics for people diagnosed with 26 different cancers from 2015-2019 by cancer site, age at diagnosis, sex, and race and ethnicity, all stratified by stage at diagnosis (early, de novo metastatic, and combined). Descriptive characteristics include frequency counts, age-adjusted incidence rates, incidence rate ratios, and 95% CIs. Robustness test results are available in the data query bank by year of diagnosis.
resultsThis resource offers insights into distributions of cancer in the US. The AIR Calculator allows users to calculate representative clinical study distributions based on the sponsor-designated study size. DISCUSSION: The AIR Calculator serves as a valuable resource for planning of clinical studies, but additional data analyses are necessary for a comprehensive understanding at the study level. Comprehensive data collection and alignment across industry are essential to ensure consistent, accurate, and transparent benchmarks in historically underrepresented patient populations and to track progress toward the goal of improving their representation in clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.